Demographic, itinerary, and laboratory characteristics of GeoSentinel Zika patients from Africa, Asia, and the Pacific.

<p>Demographic, itinerary, and laboratory characteristics of GeoSentinel Zika patients from Africa, Asia, and the Pacific.</p

Risk categorization by major international bodies.

<p>Risk categorization by major international bodies.</p

Place of exposure and place of diagnosis (arrows) of GeoSentinel Zika patients from Africa (green dot), Asia (red dots), and the Pacific (blue dots)—Circular arrows indicate cases in international travelers who contracted Zika while abroad and were diagnosed in the country of exposure while traveling.

<p>Linear arrows indicate cases in international travelers who contracted Zika while abroad and had their diagnosis confirmed on returning to their home country.—Base map is available free of charge from <a href="http://www.histgeo.ac-aix-marseille.fr/ancien_site/carto/" target="_blank">http://www.histgeo.ac-aix-marseille.fr/ancien_site/carto/</a>.</p

Temporal association of endemic and exported cases with travel notices by international authorities for selected countries in Africa.

<p>Temporal association of endemic and exported cases with travel notices by international authorities for selected countries in Africa.</p

JIKI trial: participants’ characteristics, according to age and baseline Ct value.

<p>JIKI trial: participants’ characteristics, according to age and baseline Ct value.</p

JIKI trial mortality, according to age and baseline RT-PCR Ct value.

<p>Histograms represent mortality percentages. Vertical bars represent 95% confidence intervals. Red bars represent target values. The RT-PCR assay was conducted using the RealStar Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics).</p

JIKI trial: correlation between EBOV RT-PCR Ct value and RNA viral load at baseline in adolescents and adults.

<p>The black line represents the regression line. The Spearman rank correlation coefficient was 0.88 (<i>p</i> < 0.001). A baseline Ct value of 20 corresponded to an RNA viral load of 5 × 10⁷ genome copies/ml of plasma (7.7 log₁₀ copies/ml). Of the 99 adolescents and adults, 84 had both an RT-PCR Ct and an RNA viral load measurement at baseline. Red dots represent patients who died. Blue dots represent patients who survived.</p

JIKI trial progress.

<p>ALIMA, Alliance for International Medical Action; CRF, Croix Rouge Française (French Red Cross); EU, European Union; Inserm, Institut National de la Santé et de la Recherche Médicale; SSA, Service de Santé des Armées (French military health service).</p

JIKI trial: baseline serum creatinine in adolescents and adults and outcomes according to baseline values.

<p>Creat, creatinine.</p

JIKI trial: evolution of RT-PCR Ct values and RNA viral load in adolescents and adults.

<p>(A) Evolution of RT-PCR Ct values. (B) Evolution of RNA viral loads. The <i>x</i>-axis represents the time since first symptoms (for example, for a patient whose first symptom occurred 5 d before admission to the treatment center, the baseline value dot is positioned at 5 d). Each line represents one patient. Dots represent baseline values, X’s represent follow-up values, and asterisks represent values below the limit of quantification. Red symbols represent patients who died; blue symbols represent patients who survived.</p